Sign in
Taking people in United StatesPhase 2

Metyrapone compared with placebo for mild autonomous cortisol secretion

Tests metyrapone against placebo in adults with mild autonomous cortisol secretion.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
Oct 2026
Expected to end
Dec 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Metyrapone 250 mg Oral Tablets
  • Placebo
Record updated
25 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild autonomous cortisol secretion (MACS), where the adrenal glands make slightly too much cortisol on their own. It compares overnight metyrapone with a placebo (dummy pill).

Age
18 years and older
Sex
All sexes
Disease stage
MACS with a benign (non-cancer) look on adrenal imaging, such as adrenal adenoma or macronodular or micronodular adrenal hyperplasia. People must also have at least one of: obesity (BMI>30 kg/m2), abnormal blood sugar, abnormal blood fats, high blood pressure, osteopenia, osteoporosis or fragility fractures.
Earlier treatment
People cannot join if they now take or plan to take oral glucocorticoids, or opioids >20 MME/day. No injectable glucocorticoid within 6 weeks before Day 1.
Biomarker or test result
At least 2 abnormal dexamethasone suppression test results: 1 mg post-dexamethasone cortisol >1.8 mcg/dL or 8 mg post-dexamethasone cortisol >1 mcg/dL. Results from within 24 months before enrolment can be used.

Main reasons for not taking part

  • Other treatment for MACS planned within 12 months of joining
  • Pregnancy or breastfeeding
  • Known allergy to metyrapone
  • Uncontrolled illness, such as active infection, heart failure with symptoms, unstable angina or irregular heartbeat
  • Suspected false positive dexamethasone test results

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Provide written informed consent
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Age ≥ 18 years
  • Diagnosed with MACS i. at least 2 abnormal post-dexamethasone cortisol results1 mg post-dexamethasone cortisol >1.8 mcg/dL or ii. 8 mg post-dexamethasone cortisol >1 mcg/dL b. Historical dexamethasone suppression test results can be used if performed within 24 months prior to enrollment
  • Adrenal imaging phenotype consistent with benign disease (adrenal adenoma/s, macronodular or micronodular adrenal hyperplasia)
  • At least one of the following comorbidities:; obesity (BMI>30 kg/m2); dysglycemia; dyslipidemia; hypertension; osteopenia; osteoporosis; fragility fractures
  • Ability to take oral medication and be willing to adhere to the study intervention regimen
  • For persons of childbearing potential: : agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ≤ 5% per year during the treatment period and for 1 month after the last dose of study treatment
  • Stable timing for bedtime for at least one week prior to on-site study visits
  • History of difficulty providing blood via standard blood draw methods

Who cannot take part

  • Planned alternative therapy for MACS within 12 months after joining the study
  • Current use of oral exogenous glucocorticoid therapy
  • Current use of opioid therapy >20 MME/day
  • Planned use of oral exogenous glucocorticoid therapy
  • Planned use of opioid therapy >20 MME/day
  • Use of injectable glucocorticoid within 6 weeks prior to Day 1
  • Investigator's judgement based on history/physical examination that a comorbidity or concomitant medication may impact the hypothalamic-pituitary-adrenal axis or steroid metabolome
  • Suspected false positive post-dexamethasone cortisol results due to increased metabolism, poor absorption, or noncompliance with dexamethasone
  • Treatment with another investigational drug or other intervention within lower than specific therapy washout period
  • Uncontrolled intercurrent illness including, but not limited to:; Ongoing or active infection; Symptomatic congestive heart failure; Unstable angina pectoris; Cardiac arrhythmia; Psychiatric illness/social situations that would limit compliance with study requirements
  • Known allergic reactions to metyrapone
  • Pregnancy or lactation

Where in United States

  • Mayo ClinicRochester, United StatesContact: Vanessa Fell, MATaking people

About the trial

What the trial wants to find out

single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.

The 2 groups in the trial

  • MetyraponeTreatment being tested

    Subjects in the Metyrapone arm will receive the study drug

    Treatment: Metyrapone 250 mg Oral Tablets

  • PlaceboPlacebo, for comparison

    Subjects in the placebo arm will receive a placebo in lieu of study drug

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Metyrapone in Subjects Diagnosed With Mild Autonomous Cortisol Secretion (MACS)
Plain-language title
Metyrapone compared with placebo for mild autonomous cortisol secretionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
25 September 2026